APH — Alliance Pharma Income Statement
0.000.00%
Last trade - 00:00
- £237.04m
- £332.02m
- £180.68m
- 46
- 67
- 83
- 76
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 136 | 130 | 163 | 167 | 181 |
Cost of Revenue | |||||
Gross Profit | 86.1 | 82.8 | 109 | 102 | 105 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 100 | 113 | 142 | 185 | 219 |
Operating Profit | 35.6 | 16.3 | 21.6 | -17.7 | -38.4 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 31.1 | 13 | 18.2 | -23.1 | -48.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | 25 | 8.03 | 7.32 | -21.2 | -33.1 |
Net Income Before Extraordinary Items | |||||
Net Income | 25 | 8.03 | 7.32 | -21.2 | -33.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 25 | 8.03 | 7.32 | -21.2 | -33.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.052 | 0.043 | 0.025 | 0.063 | 0.116 |
Dividends per Share |